Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Using Adalimumab Serum Concentration to Choose a Subsequent Biological DMARD in Rheumatoid Arthritis Patients Failing Adalimumab Treatment: a Blinded Randomized Superiority Trial

NCT04251741 is registered in ClinicalTrials.gov with Reade Rheumatology Research Institute as lead sponsor.

NCT NCT04251741
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04251741 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Using Adalimumab Serum Concentration to Choose a Subsequent Biological DMARD in Rheumatoid Arthritis Patients Failing Adalimumab Treatment: a Blinded Randomized Superiority Trial
Lead sponsor
Reade Rheumatology Research Institute
Phase
Phase 4
Overall status
Unknown status
Start date
July 31, 2020
Completion date
May 1, 2024
Enrollment
86 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis